aTYR PHARMA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 7.52K shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-03-31 was 900.00 shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 8.42K shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 0.00 shares.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- aTYR PHARMA INC share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 259.00 shares, a 97.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 8.42K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2025-06-30 | 7.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | |
| 2025-03-31 | 900.00 shares 10-Q · filed 2025-05-07 | |
| 2024-12-31 | 0.00 shares 10-K · filed 2026-03-05 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2026-03-05 | |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 259.00 shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 837.00 shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 10.46K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 259.00 shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 578.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 10.75K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 9.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | 12.14K shares 10-K · filed 2019-03-26 |
| 2018-09-30 | 8.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | 55.21K shares derived: sum of 4 quarters · filed 2018-11-14 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | 52.73K shares derived: sum of 4 quarters · filed 2018-08-14 |
| 2018-03-31 | 3.59K shares 10-Q · filed 2018-05-15 | 78.09K shares derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-12-31 | 43.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | 75.29K shares 10-K · filed 2018-03-20 |
| 2017-09-30 | 6.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | 32.22K shares derived: sum of 4 quarters · filed 2017-11-14 |
| 2017-06-30 | 25.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 27.00K shares derived: sum of 4 quarters · filed 2017-08-14 |
| 2017-03-31 | 795.00 shares 10-Q · filed 2017-05-11 | 11.54K shares derived: sum of 4 quarters · filed 2017-05-11 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | 15.89K shares 10-K · filed 2017-03-16 |
| 2016-09-30 | 847.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 46.69K shares derived: sum of 4 quarters · filed 2016-11-14 |
| 2016-06-30 | 9.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | 45.84K shares derived: sum of 4 quarters · filed 2016-08-10 |
| 2016-03-31 | 5.14K shares 10-Q · filed 2016-05-11 | |
| 2015-12-31 | 30.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | 197.25K shares 10-K · filed 2016-03-30 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |